Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
About cerbomed GmbH
is a privately-held medical device company that has developed a neurostimulation device,
, for the treatment of drug-resistant epilepsy. Cerbo
is developing its transcutaneous (non-invasive) vagus nerve stimulation technology, t-VNS, for a variety of other neurological disorders, including depression and migraine, as well.
's lead investor,
, is one of
's largest venture capital funds. Other investors include state-owned KfW Banking Group and S-Refit AG. Additional information on cerbo
t-VNS technology is available at
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "could," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning investing up to € 5.5 million in cerbo
, developing and commercializing cerbo
's non-invasive neurostimulation device for the treatment of epilepsy, initiating and completing a pivotal clinical study in the U.S., and obtaining U.S. marketing approval for cerbo
's non-invasive neurostimulation device for the treatment of epilepsy. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with any governmental inquiries and any litigation relating thereto, and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended
April 27, 2012
and our Quarterly Report on Form 10-Q for the fiscal quarter ended
July 27, 2012
, CFOCyberonics, Inc.100 Cyberonics Blvd.
77058Phone: (281) 228-7262Fax: (281) 218-9332
Martin Hyca, Director Marketing & Sales cerbo
GmbHHenkestraße 91 91052 Erlangen,
Phone : 0049 9131 9202 76 30E-mail :
SOURCE Cyberonics, Inc.